European Journal of Endocrinology最新文献

{"title":"Primary hyperparathyroidism induces erythropoietin resistance through fibroblast growth factor 23.","authors":"Aurélie Huber, Marco Demarchi, Thomas Verissimo, Marylise Fernandez, Anne Dufey, Lena Berchtold, Delal Dalga, Frédéric Triponez, Samira M Sadowski, Belen Ponte, Sophie de Seigneux","doi":"10.1093/ejendo/lvaf039","DOIUrl":"10.1093/ejendo/lvaf039","url":null,"abstract":"<p><strong>Introduction: </strong>Primary hyperparathyroidism (PHPT) often causes hypercalcemia and complications requiring parathyroidectomy (PTX). Anemia affects 15%-50% of PHPT patients, but its mechanisms remain unclear. While parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23) contribute to anemia in secondary hyperparathyroidism through erythropoietin (EPO) resistance and bone marrow fibrosis, their roles in PHPT are less defined. This study explores the effect of PHPT on erythropoiesis by assessing hemoglobin (Hb), EPO, and FGF23 levels before and after PTX.</p><p><strong>Methods: </strong>In a monocentric longitudinal study (2018-2020), PHPT patients scheduled for PTX were followed for 6 months. Blood and urine samples were collected at baseline (surgery day), at 10 days and 6 months postsurgery. Pearson correlation assessed relationships between Hb, EPO, PTH, FGF23, calcium, and phosphate at baseline and 6 months. Mixed-effects models evaluated the impact of PTH and FGF23 on Hb, adjusting for confounders.</p><p><strong>Results: </strong>In a cohort of 111 PHPT patients (81% women, median age 64, normal body mass index), anemia prevalence decreased from 9.9% at baseline to 2.7% 6 months post-PTX, despite stable EPO levels. Postsurgery, PTH, FGF23, and calcium significantly decreased. PTH did not significantly correlate with Hb or EPO at any time point. Before surgery, FGF23 negatively correlated with Hb (R = -0.20, P = .020) and positively correlated with log-EPO (R = 0.38, P < .001). Mixed-effects models showed no predictive effect of PTH on Hb. However, multivariable models indicated a significant association between FGF23 and declining Hb (β = -.01, 95% confidence interval [-0.02; -0.01]).</p><p><strong>Conclusion: </strong>Anemia in PHPT is linked to elevated FGF23 levels, potentially causing EPO resistance.</p>","PeriodicalId":11884,"journal":{"name":"European Journal of Endocrinology","volume":" ","pages":"290-298"},"PeriodicalIF":5.3,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rare ZMPSTE24 variants increase risk of hypertriglyceridemia and metabolic syndrome.","authors":"Lauriane Le Collen, Camille Desgrouas, Céline Lukas Croisier, Brunot Creugnet, Aurélie Dechaume, Bénédicte Toussaint, Emmanuel Vaillant, Souhila Amanzougarene, Emmanuel Buse Falay, Mehdi Derhourhi, Alexandre Lourdelle, Brigitte Delemer, Nathalie Bonello-Palot, Martine Vaxillaire, Catherine Badens, Philippe Froguel, Amélie Bonnefond","doi":"10.1093/ejendo/lvaf031","DOIUrl":"10.1093/ejendo/lvaf031","url":null,"abstract":"<p><strong>Objective: </strong>The global increase in the prevalence of metabolic syndrome represents a significant public health concern. Rare biallelic pathogenic variants in ZMPSTE24 have been identified as the cause of mandibuloacral dysplasia type B, ie, a lipodystrophy syndrome associated with metabolic complications. The role of monoallelic pathogenic variants in ZMPSTE24 concerning metabolic syndrome remains uncertain.</p><p><strong>Design: </strong>Case report and systematic review of literature.</p><p><strong>Methods: </strong>We investigated a Wallisian family with FPLD and metabolic syndrome via whole-exome sequencing. We performed functional analyses of an identified rare ZMPSTE24 variant. To broadly assess the effect of heterozygous pathogenic ZMPSTE24 variants on FPLD-associated phenotypes, and metabolic syndrome, we used the Human Gene Mutation Database (HGMD) and 200 K exome data from UK Biobank.</p><p><strong>Results: </strong>We investigated a Wallisian family where a 40-year-old female with metabolic syndrome was found to carry a rare heterozygous missense variant in ZMPSTE24. Functional assays showed a decreased prelamin to lamin A maturation and accelerated senescence. In silico analysis demonstrated that this variant might disrupt the lamin A binding site. We then analyzed the impact of monoallelic pathogenic ZMPSTE24 variants on metabolic traits using data from the HGMD and the UK Biobank. In HGMD, ZMPSTE24 variants carriers presented with dyslipidemia and hepatic steatosis. In the UK Biobank, monoallelic pathogenic variants were associated with an increased risk of hypertriglyceridemia, with a trend toward metabolic syndrome.</p><p><strong>Conclusions: </strong>This study underscores the association of ZMPSTE24 rare variants with metabolic disorders and emphasizes the need for further research to clarify their clinical implications.</p>","PeriodicalId":11884,"journal":{"name":"European Journal of Endocrinology","volume":" ","pages":"240-247"},"PeriodicalIF":5.3,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143491291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The PCOS Phenotype in Unselected Populations study: ethnic variation in population-based normative cut-offs for defining hirsutism.","authors":"Asmamaw Demis Bizuneh, Anju E Joham, Chau Thien Tay, Sylvia Kiconco, Arul Earnest, Raja Ram Dhungana, Larisa V Suturina, Xiaomiao Zhao, Alessandra Gambineri, Fahimeh Ramezani Tehrani, Bulent O Yildiz, Jin Ju Kim, Liangzhi Xu, Christian Chigozie Makwe, Helena J Teede, Ricardo Azziz","doi":"10.1093/ejendo/lvaf030","DOIUrl":"10.1093/ejendo/lvaf030","url":null,"abstract":"<p><strong>Objective: </strong>Hirsutism, a diagnostic feature of polycystic ovary syndrome (PCOS), is often defined using arbitrary percentile cutoffs, rather than normative cutoffs from population-based data. We aimed to define normative cutoffs for hirsutism in diverse populations.</p><p><strong>Design: </strong>Unselected population-based cluster analysis of individual participant data (IPD).</p><p><strong>Methods: </strong>The PCOS Phenotype in Unselected Populations (P-PUP) study IPD asset of community-based studies, underwent k-means cluster analysis, of directly assessed hirsutism, using the modified Ferriman-Gallwey (mFG) visual scale. The primary outcome was ethnicity-specific normative cutoffs for the mFG score. Medians and cutoffs were compared across ethnic groups.</p><p><strong>Results: </strong>We included 9829 unselected, medically unbiased participants, aged 18-45 years from 12 studies conducted across 8 countries including China, Iran, Italy, Nigeria, Russia, South Korea, Turkey, and the United States. The mFG cutoff scores for hirsutism on cluster analysis varied across ethnicities, ranging from 4 to 8. White Iranians had the highest cutoff score of 8, followed by White Italians and Black Africans of 7. Asian Han Chinese, White Russian, Turkish, and Black Americans shared a cutoff of 5; White Americans, Asian Koreans, Asian Russians, and Mixed Russians shared a cutoff of 4. Comparing medians and mFG cutoffs across ethnicities confirmed the same differences.</p><p><strong>Conclusion: </strong>This study confirms the 2023 International PCOS Guidelines recommendations defining hirsutism as an mFG score between 4 and 6 for the majority of populations studied, with few exceptions. However, we also highlight ethnic variation in mFG cutoff scores, suggesting that clinicians consider ethnicity in optimal diagnosis and personalized interventions.</p>","PeriodicalId":11884,"journal":{"name":"European Journal of Endocrinology","volume":" ","pages":"228-239"},"PeriodicalIF":5.3,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143556157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the Editor: \"Mechanisms in endocrinology: hypogonadism and metabolic health in men-novel insights into pathophysiology\".","authors":"Yu-Hsiang Lin, Tsung-Hsing Chen, Kuo-Jen Lin","doi":"10.1093/ejendo/lvaf042","DOIUrl":"10.1093/ejendo/lvaf042","url":null,"abstract":"","PeriodicalId":11884,"journal":{"name":"European Journal of Endocrinology","volume":" ","pages":"L12-L13"},"PeriodicalIF":5.3,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143582205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Income and work loss in patients with Addison's disease: a nationwide population-based study.","authors":"Stavros Stergianos, Åsa H Everhov, Jonas Söderling, Ragnhildur Bergthorsdottir, Jeanette Wahlberg, Jakob Skov, Sophie Bensing","doi":"10.1093/ejendo/lvaf022","DOIUrl":"10.1093/ejendo/lvaf022","url":null,"abstract":"<p><strong>Objective: </strong>Autoimmune Addison's disease (AAD) is associated with reduced health-related quality of life and possibly reduced employability. The aim of this study was to assess differences in income and work loss between patients with AAD and matched comparators.</p><p><strong>Design: </strong>Nationwide, cross-sectional register-based study.</p><p><strong>Methods: </strong>By linking the Swedish Addison Register and national health registers, we identified working age (18-64 years) individuals with AAD and general population comparators (matched 1:5 by sex, age, and county of residence). We assessed differences in taxable earnings and disposable income through quantile regression and differences in work loss through linear regression during 2019.</p><p><strong>Results: </strong>We identified 1140 cases with AAD and 5700 comparators (mean age 46.1 years, 48.4% men). Type 1 diabetes was prevalent in 15.7% and 1.1%, respectively. Work loss was higher in AAD; adjusted mean difference 14.4 days; 95% CI, 8.6-20. The adjusted median differences in taxable earnings and disposable income were non-significant overall at -617 (95% CI; -2317 to 1083) and -405 (95% CI; -1417 to 607) €. However, significantly lower taxable earnings and disposable income were found among patients with short education: -5303 (95% CI; -9603 to -992) and -3754 (95% CI; -6486 to -1022) €, or concomitant type 1 diabetes: -5808 (95% CI; -9937 to -1690) and -3349 (95% CI; -6203 to -506) €.</p><p><strong>Conclusion: </strong>Patients with AAD had more work loss, yet overall similar taxable earnings and disposable incomes versus comparators. Patients with AAD with shorter education or type 1 diabetes were most socioeconomically vulnerable.</p>","PeriodicalId":11884,"journal":{"name":"European Journal of Endocrinology","volume":" ","pages":"170-179"},"PeriodicalIF":5.3,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143467345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Additive effects of ALXN2420, a GH receptor antagonist, and octreotide on IGF1 suppression in vivo.","authors":"Guillaume Ravel, Xavier Gaume, Corentin Berardet, Clémentine Chalmey, Haruaki Kurasaki, Tatsuya Tomiyama, Patrick C Reid, David Duracher, Rakesh Datta, Myriam Aouadi, Michael D Culler","doi":"10.1093/ejendo/lvaf043","DOIUrl":"10.1093/ejendo/lvaf043","url":null,"abstract":"<p><strong>Objective: </strong>Acromegaly is an endocrine disorder caused by the hypersecretion of growth hormone (GH) by a benign tumor of the pituitary that leads to insulin-like growth factor-1 (IGF1) overproduction. In most patients, somatostatin analogs (SSAs), the current first-line medical therapy for acromegaly, do not normalize IGF1 levels. This study aims to investigate the pre-clinical efficacy of ALXN2420, a novel, small peptide antagonist of the growth hormone receptor (GHR), being developed as a combination therapy to SSAs to further suppress and normalize IGF1 levels.</p><p><strong>Design: </strong>In vitro and in vivo experiments were performed to investigate the efficacy of ALXN2420 in antagonizing the GHR and in reducing circulating IGF1 levels.</p><p><strong>Methods: </strong>The binding affinity of ALXN2420 to GHR was determined by Surface Plasmon Resonance (SPR), and inhibition of GH-induced GHR activation was investigated in vitro in primary hepatocytes. The efficacy of ALXN2420 in suppressing IGF1 levels was evaluated in rats and dogs. The ability of ALXN2420 to reduce growth was determined in the juvenile rat model. Ultimately, the effect of combining ALXN2420 with a SSA in suppressing IGF1 was examined in rats.</p><p><strong>Results: </strong>ALXN2420 bound to the human GHR and inhibited its activation by GH in vitro. In vivo, ALXN2420 administration efficiently reduced IGF1 levels, which was associated with reduced growth in juvenile rats. Importantly, when combined with a SSA, ALXN2420 demonstrated an additive effect on IGF1 reduction.</p><p><strong>Conclusion: </strong>These results support the investigation of ALXN2420 as a combination therapy for the treatment of patients with acromegaly inadequately controlled by SSAs.</p>","PeriodicalId":11884,"journal":{"name":"European Journal of Endocrinology","volume":" ","pages":"299-307"},"PeriodicalIF":5.3,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Delphi panel consensus on recommendations for thromboprophylaxis of venous thromboembolism in endogenous Cushing's syndrome: a position statement.","authors":"Kristina Isand, Hiroshi Arima, Jerome Bertherat, Olaf M Dekkers, Richard A Feelders, Maria Fleseriu, Monica R Gadelha, Jose Miguel Hinojosa-Amaya, Niki Karavitaki, Frederikus A Klok, Ann McCormack, John Newell-Price, Sue Pavord, Martin Reincke, Saurabh Sinha, Elena Valassi, John Wass, Alberto M Pereira Arias","doi":"10.1093/ejendo/lvaf017","DOIUrl":"10.1093/ejendo/lvaf017","url":null,"abstract":"<p><p>The objective of this study was to establish recommendations for thromboprophylaxis in patients with endogenous Cushing's syndrome (CS), addressing the elevated risk of venous thromboembolism (VTE) associated with hypercortisolism. A Delphi method was used, consisting of 4 rounds of voting and subsequent discussions. The panel included 18 international experts from 11 countries and 4 continents. Consensus was defined as ≥75% agreement among participants. Recommendations were structured into the following categories: thromboprophylaxis, perioperative management, and VTE treatment. Consensus was reached on several critical areas, resulting in 14 recommendations. Key recommendations include: thromboprophylaxis should be considered at time of CS diagnosis and continued for 3 months after biochemical remission, provided there are no obvious contraindications. The standard weight-based prophylactic dose of low molecular-weight heparin is the preferred agent for thromboprophylaxis in patients with CS. Additionally, perioperatively and around inferior petrosal sinus sampling, thromboprophylaxis should be reconsidered if not already initiated at diagnosis. For VTE treatment, extended thromboprophylaxis is advised continuing for 3 months after Cushing is resolved. These Delphi consensus-based recommendations aim to standardize care practices and enhance patient outcomes in CS by providing guidance on thromboprophylaxis, including its initiation and continuation across various disease states, as well as the preferred agents to use. The panel also highlighted key areas for further research, particularly regarding the use of direct oral anticoagulants in CS and the management of mild CS and mild autonomous cortisol secretion. Additionally, the optimal duration of anticoagulant prophylaxis following curative treatment remains uncertain.</p>","PeriodicalId":11884,"journal":{"name":"European Journal of Endocrinology","volume":" ","pages":"R17-R27"},"PeriodicalIF":5.3,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143457350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evolution of cardiovascular risk factors and the risk for cardiovascular events in a Caucasian population with polycystic ovary syndrome.","authors":"Alessandra Gambineri, Simona Rosa, Srdjan Pandurevic, Carolina Cecchetti, Laura Rotolo, Paola Dionese, Elisabetta Belardinelli, Beatrice Solmi, Guido Zavatta, Flaminia Fanelli, Paola Rucci, Francesco Angeli, Matteo Armillotta, Luca Bergamaschi, Enrico Gallitto, Mauro Gargiulo, Djuro Macut, Carmine Pizzi, Uberto Pagotto","doi":"10.1093/ejendo/lvaf027","DOIUrl":"10.1093/ejendo/lvaf027","url":null,"abstract":"<p><strong>Objective: </strong>To estimate the risk of cardiovascular (CV) events (primary aim) and to evaluate the long-term variation in CV risk factors in a Caucasian population of women with polycystic ovary syndrome (PCOS).</p><p><strong>Design: </strong>Matched cohort prospective study based on 10 years of follow-up.</p><p><strong>Methods: </strong>One hundred twenty Caucasian women with PCOS diagnosed by the National Institutes of Health criteria in reproductive age were assessed at baseline (2009) and at the end of follow-up (2020) for major and minor CV events and CV risk factors. Five controls were exactly matched by age and the presence/absence of type 2 diabetes with each participant at baseline (total number = 600) and followed up to evaluate the relative risk of PCOS for CV events. Change in epicardial fat thickness (EFT) was also analysed.</p><p><strong>Results: </strong>The mean age of patients with PCOS at follow-up was 51.9 ± 7.7 years. No major CV events were detected in PCOS patients (0% vs. 2% among controls), and the incidence of any minor CV events was 4.2% vs. 2.3% among controls (P = .340). The percentage of most CV risk factors (obesity, type 2 diabetes, hypertension, dyslipidaemia, and carotid intima media thickness ≥1 mm with or without plaques with non-critical stenosis) increased. By contrast, both short- and long-axis EFTs and smoking decreased markedly.</p><p><strong>Conclusions: </strong>Caucasian patients with PCOS do not have an increased risk for CV events during the late reproductive or early post-menopausal period, despite the increase in most CV risk factors, except for EFT that markedly decreases. Further studies are needed to determine the role of EFT on CV risk in PCOS.</p>","PeriodicalId":11884,"journal":{"name":"European Journal of Endocrinology","volume":" ","pages":"210-219"},"PeriodicalIF":5.3,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143556223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Decoding lymph node skip metastasis: impact on long-term outcomes in stage T1 papillary thyroid carcinoma.","authors":"Sijia Cai, Chao Qin, Meilin Liu, Yanxi Liu, Haitao Tang, Weibo Xu, Min Yin, Qinghai Ji, Tian Liao, Yu Wang","doi":"10.1093/ejendo/lvaf050","DOIUrl":"10.1093/ejendo/lvaf050","url":null,"abstract":"<p><strong>Background: </strong>Skip metastasis of lateral cervical lymph nodes not uncommonly occurs in early papillary thyroid carcinoma (PTC), which represents a heterogeneous metastasis type. Currently, few studies report on the relationship between skip metastasis and prognosis or propose treatment recommendations.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on patients with unilateral T1-stage PTC who underwent lobectomy between 2007 and 2015. Patients with skipping N1b (sN1b) stage were included, and propensity score matching (PSM) was applied to incorporate patients from both N1a and N1b stages for comparison. Kaplan-Meier method was employed to compare recurrence-free survival (RFS) among different groups, and lymph node metastasis patterns in sN1b group as well as their impacts on prognosis were evaluated.</p><p><strong>Results: </strong>The initial cohort comprised 1188 patients, and after adjusting for baseline clinicopathological data and follow-up duration, a total of 372 patients were included with an average follow-up time of 82 months. The recurrence rates in the N1a, sN1b, and N1b groups after PSM were 8.9%, 11.3%, and 12.9%, respectively. Notably, RFS did not differ significantly between sN1b and N1a (P = .65) or N1b (P = .66). Furthermore, the number of positive lymph nodes in the sN1b group was comparable to N1a group (P = .77) but significantly lower than N1b group (P < .0001). Remarkably, the risk stratification based on the lymph node positivity rate (LNPR) in the sN1b group demonstrated a strong prognostic discrimination (P = .0067).</p><p><strong>Conclusion: </strong>The RFS among stage T1 PTC patients with sN1b stage was comparable to those with N1a and N1b stages. LNPR risk stratification emerged as a significant prognostic factor.</p>","PeriodicalId":11884,"journal":{"name":"European Journal of Endocrinology","volume":" ","pages":"318-326"},"PeriodicalIF":5.3,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143633829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response by Yuk et al. to letter regarding article, \"Association of menopausal hormone therapy with risk of cardiovascular disease in Korean women\".","authors":"Jin-Sung Yuk, Gwang Sil Kim, Dong-Gil Kim, Young Sup Byun, Myoung-Hwan Kim, Sang-Hee Yoon, Gwan Hee Han, Byung Gyu Kim","doi":"10.1093/ejendo/lvaf041","DOIUrl":"10.1093/ejendo/lvaf041","url":null,"abstract":"","PeriodicalId":11884,"journal":{"name":"European Journal of Endocrinology","volume":" ","pages":"L14-L15"},"PeriodicalIF":5.3,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143614115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}